[HTML][HTML] Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
Effective SARS-CoV-2 vaccines are urgently needed. Although most vaccine strategies have
focused on systemic immunization, here we compared the protective efficacy of 2 …
focused on systemic immunization, here we compared the protective efficacy of 2 …
[HTML][HTML] SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
F Liew, S Talwar, A Cross, BJ Willett, S Scott… - …, 2023 - thelancet.com
Background Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving
limited insights into mucosal defences that prevent viral replication and onward …
limited insights into mucosal defences that prevent viral replication and onward …
Mucosal vaccines for SARS-CoV-2: triumph of hope over experience
D Pilapitiya, AK Wheatley, HX Tan - EBioMedicine, 2023 - thelancet.com
Currently approved COVID-19 vaccines administered parenterally induce robust systemic
humoral and cellular responses. While highly effective against severe disease, there is …
humoral and cellular responses. While highly effective against severe disease, there is …
Intranasal vaccine: Factors to consider in research and development
H Xu, L Cai, S Hufnagel, Z Cui - International journal of pharmaceutics, 2021 - Elsevier
Most existing vaccines for human use are administered by needle-based injection.
Administering vaccines needle-free intranasally has numerous advantages over by needle …
Administering vaccines needle-free intranasally has numerous advantages over by needle …
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models
N van Doremalen, JN Purushotham… - Science translational …, 2021 - science.org
ChAdOx1 nCoV-19/AZD1222 is an approved adenovirus-based vaccine for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being deployed globally …
respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being deployed globally …
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses
H Ishii, T Nomura, H Yamamoto, M Nishizawa… - Cell Reports …, 2022 - cell.com
Effective vaccines are essential for the control of the coronavirus disease 2019 (COVID-19)
pandemic. Currently developed vaccines inducing severe acute respiratory syndrome …
pandemic. Currently developed vaccines inducing severe acute respiratory syndrome …
Nasal and salivary mucosal humoral immune response elicited by mRNA BNT162b2 COVID-19 vaccine compared to SARS-CoV-2 natural infection
M Guerrieri, B Francavilla, D Fiorelli, M Nuccetelli… - Vaccines, 2021 - mdpi.com
SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic. Approved
mRNA COVID-19 vaccines are well known to induce a serum antibody responses against …
mRNA COVID-19 vaccines are well known to induce a serum antibody responses against …
An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in …
K Tabynov, M Solomadin, N Turebekov, M Babayeva… - Scientific Reports, 2023 - nature.com
We developed a novel intranasal SARS-CoV-2 subunit vaccine called NARUVAX-C19/Nano
based on the spike protein receptor-binding domain (RBD) entrapped in mannose …
based on the spike protein receptor-binding domain (RBD) entrapped in mannose …